Compare HOLX & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLX | TEVA |
|---|---|---|
| Founded | 1985 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 30.2B |
| IPO Year | 1990 | N/A |
| Metric | HOLX | TEVA |
|---|---|---|
| Price | $75.01 | $29.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $79.64 | $29.78 |
| AVG Volume (30 Days) | 2.9M | ★ 10.4M |
| Earning Date | 11-03-2025 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.49 | 0.62 |
| Revenue | $4,100,500,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $6.69 | $4.74 |
| Revenue Next Year | $5.74 | $0.48 |
| P/E Ratio | ★ $30.05 | $48.90 |
| Revenue Growth | ★ 1.74 | 0.02 |
| 52 Week Low | $51.90 | $12.47 |
| 52 Week High | $76.29 | $30.20 |
| Indicator | HOLX | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 68.00 | 79.52 |
| Support Level | $74.77 | $28.00 |
| Resistance Level | $75.05 | $30.20 |
| Average True Range (ATR) | 0.30 | 0.65 |
| MACD | -0.14 | 0.18 |
| Stochastic Oscillator | 86.93 | 92.58 |
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.